212 related articles for article (PubMed ID: 33076721)
1. CBTp for people with treatment refractory schizophrenia on clozapine: a systematic review and meta-analysis.
Todorovic A; Lal S; Dark F; De Monte V; Kisely S; Siskind D
J Ment Health; 2023 Feb; 32(1):321-328. PubMed ID: 33076721
[TBL] [Abstract][Full Text] [Related]
2. Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis.
Siskind DJ; Lee M; Ravindran A; Zhang Q; Ma E; Motamarri B; Kisely S
Aust N Z J Psychiatry; 2018 Aug; 52(8):751-767. PubMed ID: 29732913
[TBL] [Abstract][Full Text] [Related]
3. Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial.
Morrison AP; Pyle M; Gumley A; Schwannauer M; Turkington D; MacLennan G; Norrie J; Hudson J; Bowe SE; French P; Byrne R; Syrett S; Dudley R; McLeod HJ; Griffiths H; Barnes TRE; Davies L; Kingdon D;
Lancet Psychiatry; 2018 Aug; 5(8):633-643. PubMed ID: 30001930
[TBL] [Abstract][Full Text] [Related]
4. Cognitive Behavioral Therapy for Prodromal Stage of Psychosis-Outcomes for Transition, Functioning, Distress, and Quality of Life: A Systematic Review and Meta-analysis.
Zheng Y; Xu T; Zhu Y; Li C; Wang J; Livingstone S; Zhang T
Schizophr Bull; 2022 Jan; 48(1):8-19. PubMed ID: 33944949
[TBL] [Abstract][Full Text] [Related]
5. Cognitive Behavioural Therapy for schizophrenia - outcomes for functioning, distress and quality of life: a meta-analysis.
Laws KR; Darlington N; Kondel TK; McKenna PJ; Jauhar S
BMC Psychol; 2018 Jul; 6(1):32. PubMed ID: 30016999
[TBL] [Abstract][Full Text] [Related]
6. Cognitive behavioural therapy (brief versus standard duration) for schizophrenia.
Naeem F; Farooq S; Kingdon D
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010646. PubMed ID: 26488686
[TBL] [Abstract][Full Text] [Related]
7. Cognitive behavioural therapy (brief versus standard duration) for schizophrenia.
Naeem F; Farooq S; Kingdon D
Cochrane Database Syst Rev; 2014 Apr; (4):CD010646. PubMed ID: 24723312
[TBL] [Abstract][Full Text] [Related]
8. Cognitive Behavioural Therapy for Psychosis: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2018; 18(5):1-141. PubMed ID: 30443277
[TBL] [Abstract][Full Text] [Related]
9. Cognitive-behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT.
Morrison AP; Pyle M; Gumley A; Schwannauer M; Turkington D; MacLennan G; Norrie J; Hudson J; Bowe S; French P; Hutton P; Byrne R; Syrett S; Dudley R; McLeod HJ; Griffiths H; Barnes TR; Davies L; Shields G; Buck D; Tully S; Kingdon D
Health Technol Assess; 2019 Feb; 23(7):1-144. PubMed ID: 30806619
[TBL] [Abstract][Full Text] [Related]
10. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis.
Siskind D; McCartney L; Goldschlager R; Kisely S
Br J Psychiatry; 2016 Nov; 209(5):385-392. PubMed ID: 27388573
[TBL] [Abstract][Full Text] [Related]
11. Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial.
Pyle M; Norrie J; Schwannauer M; Kingdon D; Gumley A; Turkington D; Byrne R; Syrett S; MacLennan G; Dudley R; McLeod HJ; Griffiths H; Bowe S; Barnes TR; French P; Hutton P; Davies L; Morrison AP
BMC Psychiatry; 2016 Aug; 16():280. PubMed ID: 27496180
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis.
Tiihonen J; Wahlbeck K; Kiviniemi V
Schizophr Res; 2009 Apr; 109(1-3):10-4. PubMed ID: 19186030
[TBL] [Abstract][Full Text] [Related]
13. Group cognitive behavioural therapy for psychosis in the Asian context: a review of the recent studies.
Wong JPS; Ting KT; Wong AWS
Int Rev Psychiatry; 2019; 31(5-6):460-470. PubMed ID: 31340692
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
Singh SP; Singh V
CNS Drugs; 2011 Oct; 25(10):859-85. PubMed ID: 21936588
[TBL] [Abstract][Full Text] [Related]
15. Sensorimotor gating and clinical outcome following cognitive behaviour therapy for psychosis.
Kumari V; Premkumar P; Fannon D; Aasen I; Raghuvanshi S; Anilkumar AP; Antonova E; Peters ER; Kuipers E
Schizophr Res; 2012 Feb; 134(2-3):232-8. PubMed ID: 22138048
[TBL] [Abstract][Full Text] [Related]
16. Early Non-Response to Antipsychotic Treatment in Schizophrenia: A Systematic Review and Meta-Analysis of Evidence-Based Management Options.
Rubio JM; Guinart D; Kane JM; Correll CU
CNS Drugs; 2023 Jun; 37(6):499-512. PubMed ID: 37261669
[TBL] [Abstract][Full Text] [Related]
17. Identification of the delivery of cognitive behavioural therapy for psychosis (CBTp) using a cross-sectional sample from electronic health records and open-text information in a large UK-based mental health case register.
Colling C; Evans L; Broadbent M; Chandran D; Craig TJ; Kolliakou A; Stewart R; Garety PA
BMJ Open; 2017 Jul; 7(7):e015297. PubMed ID: 28716789
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis of low intensity CBT for psychosis.
Hazell CM; Hayward M; Cavanagh K; Strauss C
Clin Psychol Rev; 2016 Apr; 45():183-92. PubMed ID: 27048980
[TBL] [Abstract][Full Text] [Related]
19. Pituitary volume reduction in schizophrenia following cognitive behavioural therapy.
Premkumar P; Bream D; Sapara A; Fannon D; Anilkumar AP; Kuipers E; Kumari V
Schizophr Res; 2018 Feb; 192():416-422. PubMed ID: 28434719
[TBL] [Abstract][Full Text] [Related]
20. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
Barnes TR; Leeson VC; Paton C; Marston L; Davies L; Whittaker W; Osborn D; Kumar R; Keown P; Zafar R; Iqbal K; Singh V; Fridrich P; Fitzgerald Z; Bagalkote H; Haddad PM; Husni M; Amos T
Health Technol Assess; 2017 Sep; 21(49):1-56. PubMed ID: 28869006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
